Multi-peptide Vaccination Adjuvanted With XS15 in Acute Myeloid Leukemia Patients
Status:
NOT_YET_RECRUITING
Trial end date:
2026-11-02
Target enrollment:
Participant gender:
Summary
The aim of this Phase I study is to evaluate the immunogenicity along with safety and toxicity as well as first efficacy of a multi-peptide vaccine adjuvanted with the TLR1/2 ligand XS15 emulsified in Montanide ISA 51 VG (AML-VAC-XS15) in AML patients who have achieved CR or CRi with first line treatment.